MD ANDERSON CANCER CENTER and AstraZeneca announced a multiyear strategic research collaboration to conduct multiple, parallel clinical and clinically related studies in ovarian and other gynecologic cancers, including epidemiological and outcomes studies.
TONY HUNTER, CHARLES SAWYERS, and JOSEPH SCHLESSINGER received the Frontiers of Knowledge Award in Biomedicine from the BBVA Foundation for their work in on personalized treatments of cancer.
COLUMBIA UNIVERSITY has eliminated its mesothelioma center after its director, Robert Taub, was reported to have had a long-running association with the former New York State Assembly Speaker Sheldon Silver.
JAMES ORR was appointed chair of the Florida Board of Medicine. Orr is medical director of Florida Gynecologic Oncology, a division of 21st Century Oncology. He will direct the actions of the board that oversees 68,000 Florida physicians.
FDA expanded the approved use of Imbruvica (ibrutinib) for previously treated patients with Waldenström's macroglobulinemia. The drug received a breakthrough therapy designation for this use.
Amgen and its subsidiary Onyx Pharmaceuticals Inc. announced the submission of a supplemental New Drug Application to FDA and a Marketing Authorization Application to the European Medicines Agency for Kyprolis (carfilzomib) for Injection in relapsed multiple myeloma.
Array BioPharma Inc. reached an agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in phase III development. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals.
Health Canada granted a Class 3 Device License approval for the xTAG CYP2D6 Kit v3 genotyping assay, developed by Luminex Corporation.
SCOTT STRONG was named as chief of the Division of Gastrointestinal and Oncologic Surgery at Northwestern Memorial Hospital and surgical director of the Digestive Health Center.
FDA granted orphan drug designation to tarextumab (anti-Notch 2/3, OMP-59R5) for the treatment of both pancreatic cancer and small cell lung cancer.
